Axsome Therapeutics Inc. (AXSM) Now Covered by Analysts at Brean Capital
Other research analysts also recently issued reports about the company. Cantor Fitzgerald set a $13.00 price target on Axsome Therapeutics and gave the company a buy rating in a report on Wednesday, August 10th. Zacks Investment Research upgraded Axsome Therapeutics from a sell rating to a hold rating in a report on Wednesday, July 27th.
Shares of Axsome Therapeutics (NASDAQ:AXSM) traded down 0.24% during mid-day trading on Monday, reaching $8.25. The company’s stock had a trading volume of 15,443 shares. The firm has a 50-day moving average of $7.47 and a 200-day moving average of $8.40. Axsome Therapeutics has a 52 week low of $5.37 and a 52 week high of $15.74. The firm’s market capitalization is $157.98 million.
A number of hedge funds have recently made changes to their positions in the stock. Teachers Advisors Inc. bought a new stake in shares of Axsome Therapeutics during the second quarter valued at about $128,000. Schwab Charles Investment Management Inc. bought a new stake in shares of Axsome Therapeutics during the second quarter valued at about $134,000. Bank of New York Mellon Corp bought a new stake in shares of Axsome Therapeutics during the second quarter valued at about $161,000. California State Teachers Retirement System bought a new stake in shares of Axsome Therapeutics during the second quarter valued at about $176,000. Finally, BlackRock Investment Management LLC increased its stake in shares of Axsome Therapeutics by 3,828.0% in the second quarter. BlackRock Investment Management LLC now owns 38,062 shares of the company’s stock valued at $287,000 after buying an additional 37,093 shares in the last quarter. Hedge funds and other institutional investors own 30.30% of the company’s stock.
Axsome Therapeutics Company Profile
Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies for the management of central nervous system (CNS) disorders, including pain. It operates in the business of developing novel therapies for the management of CNS disorders segment. Its product candidate, AXS-02 (disodium zoledronate tetrahydrate), is an oral, targeted, non opioid therapeutic for chronic pain.
Receive News & Stock Ratings for Axsome Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics Inc. and related stocks with our FREE daily email newsletter.